|
nasdaq:anth
|
79965
|
Jul 22nd, 2022 12:00AM
|
Anthera Pharmaceuticals
|
1.2K
|
17.00
|
Open
|
Biotechnology
|
Jul 22nd, 2022 07:56AM
|
Jul 22nd, 2022 07:56AM
|
Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. Anthera has two product candidates, Sollpura, in Phase 3 development for Exocrine Pancreatic Insufficiency due to Cystic Fibrosis and blisibimod, in Phase 2 development for IgA nephropathy.
NASDAQ: ANTH
|
Open
|
Biotechnology, Pharmaceutical, Drug Development
|
Open
|
25801 Industrial Blvd Ste B
|
Hayward
|
California
|
US
|
94545
|
|
Anthera Pharmaceuticals
|
Health Care
|
Pharmaceuticals & Biotechnology
|
|
nasdaq:anth
|
79965
|
Jul 21st, 2022 12:00AM
|
Anthera Pharmaceuticals
|
1.2K
|
17.00
|
Open
|
Biotechnology
|
Jul 21st, 2022 08:39AM
|
Jul 21st, 2022 08:39AM
|
Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. Anthera has two product candidates, Sollpura, in Phase 3 development for Exocrine Pancreatic Insufficiency due to Cystic Fibrosis and blisibimod, in Phase 2 development for IgA nephropathy.
NASDAQ: ANTH
|
Open
|
Biotechnology, Pharmaceutical, Drug Development
|
Open
|
25801 Industrial Blvd Ste B
|
Hayward
|
California
|
US
|
94545
|
|
Anthera Pharmaceuticals
|
Health Care
|
Pharmaceuticals & Biotechnology
|
|
nasdaq:anth
|
79965
|
Jul 20th, 2022 12:00AM
|
Anthera Pharmaceuticals
|
1.2K
|
17.00
|
Open
|
Biotechnology
|
Jul 20th, 2022 08:26AM
|
Jul 20th, 2022 08:26AM
|
Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. Anthera has two product candidates, Sollpura, in Phase 3 development for Exocrine Pancreatic Insufficiency due to Cystic Fibrosis and blisibimod, in Phase 2 development for IgA nephropathy.
NASDAQ: ANTH
|
Open
|
Biotechnology, Pharmaceutical, Drug Development
|
Open
|
25801 Industrial Blvd Ste B
|
Hayward
|
California
|
US
|
94545
|
|
Anthera Pharmaceuticals
|
Health Care
|
Pharmaceuticals & Biotechnology
|
|
nasdaq:anth
|
79965
|
Jul 19th, 2022 12:00AM
|
Anthera Pharmaceuticals
|
1.2K
|
17.00
|
Open
|
Biotechnology
|
Jul 19th, 2022 07:57AM
|
Jul 19th, 2022 07:57AM
|
Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. Anthera has two product candidates, Sollpura, in Phase 3 development for Exocrine Pancreatic Insufficiency due to Cystic Fibrosis and blisibimod, in Phase 2 development for IgA nephropathy.
NASDAQ: ANTH
|
Open
|
Biotechnology, Pharmaceutical, Drug Development
|
Open
|
25801 Industrial Blvd Ste B
|
Hayward
|
California
|
US
|
94545
|
|
Anthera Pharmaceuticals
|
Health Care
|
Pharmaceuticals & Biotechnology
|
|
nasdaq:anth
|
79965
|
Jul 18th, 2022 12:00AM
|
Anthera Pharmaceuticals
|
1.2K
|
17.00
|
Open
|
Biotechnology
|
Jul 18th, 2022 08:20AM
|
Jul 18th, 2022 08:20AM
|
Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. Anthera has two product candidates, Sollpura, in Phase 3 development for Exocrine Pancreatic Insufficiency due to Cystic Fibrosis and blisibimod, in Phase 2 development for IgA nephropathy.
NASDAQ: ANTH
|
Open
|
Biotechnology, Pharmaceutical, Drug Development
|
Open
|
25801 Industrial Blvd Ste B
|
Hayward
|
California
|
US
|
94545
|
|
Anthera Pharmaceuticals
|
Health Care
|
Pharmaceuticals & Biotechnology
|
|
nasdaq:anth
|
79965
|
Jul 17th, 2022 12:00AM
|
Anthera Pharmaceuticals
|
1.2K
|
17.00
|
Open
|
Biotechnology
|
Jul 17th, 2022 08:34AM
|
Jul 17th, 2022 08:34AM
|
Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. Anthera has two product candidates, Sollpura, in Phase 3 development for Exocrine Pancreatic Insufficiency due to Cystic Fibrosis and blisibimod, in Phase 2 development for IgA nephropathy.
NASDAQ: ANTH
|
Open
|
Biotechnology, Pharmaceutical, Drug Development
|
Open
|
25801 Industrial Blvd Ste B
|
Hayward
|
California
|
US
|
94545
|
|
Anthera Pharmaceuticals
|
Health Care
|
Pharmaceuticals & Biotechnology
|
|
nasdaq:anth
|
79965
|
Jul 16th, 2022 12:00AM
|
Anthera Pharmaceuticals
|
1.2K
|
17.00
|
Open
|
Biotechnology
|
Jul 16th, 2022 01:40PM
|
Jul 16th, 2022 01:40PM
|
Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. Anthera has two product candidates, Sollpura, in Phase 3 development for Exocrine Pancreatic Insufficiency due to Cystic Fibrosis and blisibimod, in Phase 2 development for IgA nephropathy.
NASDAQ: ANTH
|
Open
|
Biotechnology, Pharmaceutical, Drug Development
|
Open
|
25801 Industrial Blvd Ste B
|
Hayward
|
California
|
US
|
94545
|
|
Anthera Pharmaceuticals
|
Health Care
|
Pharmaceuticals & Biotechnology
|
|
nasdaq:anth
|
79965
|
Jul 15th, 2022 12:00AM
|
Anthera Pharmaceuticals
|
1.2K
|
17.00
|
Open
|
Biotechnology
|
Jul 15th, 2022 05:49AM
|
Jul 15th, 2022 05:49AM
|
Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. Anthera has two product candidates, Sollpura, in Phase 3 development for Exocrine Pancreatic Insufficiency due to Cystic Fibrosis and blisibimod, in Phase 2 development for IgA nephropathy.
NASDAQ: ANTH
|
Open
|
Biotechnology, Pharmaceutical, Drug Development
|
Open
|
25801 Industrial Blvd Ste B
|
Hayward
|
California
|
US
|
94545
|
|
Anthera Pharmaceuticals
|
Health Care
|
Pharmaceuticals & Biotechnology
|
|
nasdaq:anth
|
79965
|
Jul 14th, 2022 12:00AM
|
Anthera Pharmaceuticals
|
1.2K
|
17.00
|
Open
|
Biotechnology
|
Jul 14th, 2022 05:51AM
|
Jul 14th, 2022 05:51AM
|
Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. Anthera has two product candidates, Sollpura, in Phase 3 development for Exocrine Pancreatic Insufficiency due to Cystic Fibrosis and blisibimod, in Phase 2 development for IgA nephropathy.
NASDAQ: ANTH
|
Open
|
Biotechnology, Pharmaceutical, Drug Development
|
Open
|
25801 Industrial Blvd Ste B
|
Hayward
|
California
|
US
|
94545
|
|
Anthera Pharmaceuticals
|
Health Care
|
Pharmaceuticals & Biotechnology
|
|
nasdaq:anth
|
79965
|
Jul 13th, 2022 12:00AM
|
Anthera Pharmaceuticals
|
1.2K
|
17.00
|
Open
|
Biotechnology
|
Jul 13th, 2022 08:07AM
|
Jul 13th, 2022 08:07AM
|
Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. Anthera has two product candidates, Sollpura, in Phase 3 development for Exocrine Pancreatic Insufficiency due to Cystic Fibrosis and blisibimod, in Phase 2 development for IgA nephropathy.
NASDAQ: ANTH
|
Open
|
Biotechnology, Pharmaceutical, Drug Development
|
Open
|
25801 Industrial Blvd Ste B
|
Hayward
|
California
|
US
|
94545
|
|
Anthera Pharmaceuticals
|
Health Care
|
Pharmaceuticals & Biotechnology
|